Drug Profile
S 707106
Alternative Names: S-707106Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Shionogi
- Class Antihyperglycaemics; Insulin sensitisers
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 23 Jul 2015 Phase-IIa is ongoing for Type-2 diabetes mellitus in USA
- 09 May 2013 S 707106 is still in phase IIa development for Type-2 diabetes mellitus in USA
- 12 Jan 2012 Shionogi completes a phase IIa trial in Type-2 diabetes mellitus in USA (NCT01240759)